Celularity, Inc. CELU

Celularity announces an initial closing of over $10 million in gross proceeds from a private placement of senior secured convertible notes and warrants, part of a recapitalization allowing up to $25 million in new funding and the restructuring of about $3 million of existing debt. The financing follows operating improvements including reducing monthly cash burn by more than $1 million, personnel optimization and a sharper focus on revenue opportunities. With a lower cost base, a purpose-built Florham Park facility, and cenplacel-L inventory valued at about $40 million in potential sales, Celularity aims to convert assets into revenue and growth. The plan expands manufacturing relationships, including MuseCell Innovations for U.S. Dezawa MuseCell production, and seeks additional partnerships. The company expects positive monthly operating cash flow by the end of Q1 2027. Philip A. Barach will join the Board. Liquidity improves and growth initiatives funded via up to $25M in new capital and $3M debt restructuring, enabling scale manufacturing and revenue initiatives.

Celularity, Inc. signs U.S. manufacturing collaboration with potential $300 million purchase opportunity. Potential $300 million purchase opportunity marks major strategic revenue and expansion move for Celularity.

Celularity announces U.S. manufacturing collaboration with MuseCell Innovations for Dezawa MuseCell Platform. Manufacturing partnership supports scaled production of core cell therapy technology.

Celularity, Inc. (CELU) released an update on its Nasdaq listing compliance status. Nasdaq compliance updates signal delisting risks that can affect stock liquidity and valuation.

Celularity and Fountain Life announce availability of Cenplacel-L for investigational use under new Florida law, creating a scalable pathway for advancement of placental-derived cell therapies. Florida law access to Cenplacel-L establishes scalable pathway advancing Celularity placental cell therapies.

Celularity Inc. (CELU) filed its Form 10-K, regained compliance with Nasdaq listing requirements, and highlighted its ongoing strategic transformation. Regaining Nasdaq compliance removes delisting risk while strategic transformation signals major positive shifts in operations and investor confidence.

NEXGEL names Sequence LifeScience as new strategic partner, which leads $5.5 million financing to complete acquisition of Celularity's degenerative disease segment. Divestiture of degenerative disease segment provides Celularity $5.5 million in financing and enables strategic refocus on core operations.

Celularity, Inc. (CELU) announces the closing of its transaction with NexGel. Closing the transaction with NexGel marks a major strategic shift for Celularity's operations and market position.

NEXGEL reschedules its 2025 financial results conference call to April 8 at 4:30 P.M. ET to update shareholders on its previously announced transaction with Celularity. Rescheduling conference call specifically for transaction update signals potential influence on Celularity's deal progress and investor sentiment.

NEXGEL announced consideration terms of agreement to license and acquire Celularity Inc.'s (CELU) portfolio of commercial-stage regenerative biomaterial products. Celularity's portfolio licensing and acquisition by NEXGEL marks a major strategic divestiture of commercial assets with high potential to boost finances and reshape operations.

NEXGEL signs definitive agreement to license and acquire Celularity's transformative portfolio of commercial-stage regenerative biomaterial products. Celularity gains revenue stream and strategic validation by licensing commercial-stage regenerative biomaterials to NEXGEL.

Celularity Inc. (CELU) secured a $35 million strategic license deal, strengthening its capital position to advance its longevity-focused strategy. $35 million license deal delivers major capital boost to propel Celularity's core longevity initiatives and enhance financial stability.

Celularity, Inc. has successfully sold its New Jersey net operating losses for $12.2 million. This transaction is part of the company's strategy to enhance its financial position and support ongoing operations. The sale of these tax attributes is expected to provide Celularity with additional liquidity, aiding in its growth initiatives. The sale of net operating losses provides additional liquidity, which may moderately influence financial performance.

Celularity, Inc. CEO commented on the Centers for Medicare & Medicaid Services’ decision to withdraw local coverage determinations for skin substitutes, emphasizing the potential implications for patient access and reimbursement in regenerative medicine. The withdrawal may affect the market landscape for skin substitute products, which are crucial for Celularity's offerings in the field of cell-based therapies. The withdrawal of local coverage determinations could moderately influence Celularity's market positioning and financial performance in the regenerative medicine sector.

Celularity, Inc. has successfully closed financing transactions, securing $20 million through a private placement of common stock and warrants. The funds will be utilized to advance the company's innovative cell therapy programs and support ongoing operations. This financing is expected to enhance Celularity's ability to develop its product pipeline and strengthen its financial position. The financing will significantly bolster Celularity's operational capabilities and product development efforts.

Celularity, Inc. has reached binding term sheets for financing transactions aimed at supporting its strategic vision. These agreements are expected to enhance the company's financial position and facilitate its growth initiatives in the biotechnology sector. The financing transactions are likely to significantly impact Celularity's future operations and market positioning.

Celularity, Inc. has partnered with DefEYE, Inc. to enhance the development of regenerative therapies specifically for eye care. This collaboration aims to leverage Celularity's expertise in cell-based therapies and DefEYE's focus on ocular health to create innovative treatment options. The partnership is expected to accelerate advancements in regenerative medicine within the eye care sector, potentially improving patient outcomes and expanding market opportunities. The partnership is a significant strategic move that could enhance product offerings and market positioning in the regenerative therapy space.

Celularity, Inc. announced the peer-reviewed publication of Phase 2 clinical trial results for PDA-002, a treatment derived from human placenta cells, demonstrating safety and efficacy in treating diabetic foot ulcers complicated by peripheral artery disease. The study highlights the potential of PDA-002 to improve healing in patients with this condition, marking a significant advancement in regenerative medicine. The publication of positive clinical trial results is likely to significantly impact investor sentiment and the company's future performance in the regenerative medicine market.

Celularity, Inc. reported a loss of US$1.02 per share for the second quarter of 2025, compared to a loss of US$0.30 per share in the same quarter of 2024. This significant increase in losses indicates potential challenges in financial performance and operational efficiency. The increase in losses suggests moderate financial challenges that could affect investor sentiment and operational strategies.

Celularity, Inc. has successfully completed a significant balance sheet restructuring, retiring all of its $41.6 million in senior secured debt. This move is expected to enhance the company's financial stability and position it for future growth. Retiring all senior secured debt significantly improves financial health and investor sentiment.

Celularity, Inc. (NASDAQ: CELU) experienced an 11% stock price increase last week, benefiting retail investors who are among its largest shareholders. This surge in stock value has led to a notable gain in the holdings of these investors, reflecting positive market sentiment towards the company. The stock price increase indicates a moderately noticeable influence on investor sentiment and market performance.

Celularity, Inc. has partnered with Fountain Life to provide stem cell therapies in Florida, following the state's new law that allows such treatments. This collaboration aims to enhance access to innovative regenerative medicine solutions, leveraging Celularity's expertise in cellular therapies and Fountain Life's health optimization services. The partnership aligns with regulatory changes that could significantly enhance Celularity's market position and growth potential in the stem cell therapy sector.

Celularity, Inc. applauds a new Florida law effective July 1, 2025, allowing physicians to provide investigational stem cell therapies for orthopedics, wound care, and pain management. The law mandates strict sourcing and manufacturing standards for stem cells, ensuring patient safety and ethical practices. Celularity is prepared to supply ethically sourced stem cells and aims to collaborate with Florida physicians to enhance patient access to these therapies. The company emphasizes the importance of physician involvement in assessing treatment options and highlights its extensive experience in the field of stem cell therapies. The new law significantly expands the market for stem cell therapies, potentially enhancing Celularity's growth and competitive positioning.

Celularity Inc. announced research published in Regenerative Engineering and Translational Medicine, showcasing its tri-layer decellularized, dehydrated amniotic membrane (DDHAM-3L) as a novel carrier for induced pluripotent stem cell-derived limbal stem cells in treating ocular surface disorders. The study, conducted with North Carolina State University, demonstrated DDHAM-3L's ability to support cell adhesion, proliferation, and stemness, offering a scalable solution for ocular surface reconstruction. Celularity aims to leverage this technology for broader clinical applications beyond ophthalmology. The advancement of DDHAM-3L technology represents a significant step in addressing ocular surface disorders, potentially transforming treatment options and impacting market positioning.

Celularity, Inc. (CELU) announced its full year 2024 operating and financial results, highlighting key metrics and performance indicators. The company reported significant advancements in its product pipeline and operational efficiency, which are expected to enhance its market position. Financial results showed improvements in revenue and cost management, reflecting a strategic focus on growth and innovation in the biotechnology sector. Celularity's ongoing commitment to developing cellular therapies is underscored by these results, positioning the company for future opportunities. The reported advancements and financial improvements indicate a significant strategic move that could alter the company's trajectory and investor sentiment.

Celularity Inc. welcomes the Centers for Medicare & Medicaid Services' decision to delay the effective date of the Medicare Local Coverage Determination for skin substitute products to January 1, 2026. This LCD, which affects treatments for diabetic foot ulcers and venous leg ulcers, was initially set to take effect in February 2025. The delay follows an executive order by President Trump freezing regulatory guidance. Celularity's leadership emphasizes the importance of this action for patient access to critical wound care products and supports ongoing payment system reforms to improve care and reduce costs. The delay in the LCD significantly impacts patient access to Celularity's products and allows for necessary reforms in the reimbursement system.

Celularity Inc. announced the publication of a study in Frontiers in Immunology discussing the role of aging in immune response and cancer, highlighting the potential of their NK cell therapy candidate CYNK-001 in combating age-related diseases. The publication emphasizes the importance of preserving NK cell function for healthy aging and suggests that adoptive NK cell therapy could counteract immunosenescence. CEO Robert J. Hariri noted that eliminating senescent cells may alleviate negative aging effects and improve conditions like frailty and sarcopenia. CYNK-001 has been studied in over 70 subjects with acceptable safety. The publication highlights significant therapeutic potential for CYNK-001, which could influence Celularity's market position and investor sentiment.

Celularity Inc. announced it received FDA recommendation letters for its wound care products, Natalin and Acelagraft™, confirming they meet criteria for regulation under section 361 of the PHS Act. Both products are derived from decellularized dehydrated amnion and are indicated for treating partial and full thickness acute and chronic wounds. The global Biological Skin Substitutes market is projected to grow significantly, with the chronic wounds segment expected to grow at a 9.13% CAGR. Dr. Robert Hariri, CEO, expressed optimism about the products enhancing the company's commercial momentum. FDA recommendations for new wound care products are likely to significantly impact Celularity's market position and growth potential.

Celularity Inc. has entered a Master Services Collaboration Agreement with BlueSphere Bio, Inc. to manufacture certain cell therapy products, focusing initially on T cell receptor therapies for Acute Myelogenous Leukemia (AML). This partnership highlights Celularity's advanced cGMP manufacturing capabilities and aims to support BSB's clinical development while generating revenue for Celularity. The collaboration will utilize Celularity's Florham Park, NJ facility and involve comprehensive manufacturing processes, with oversight from BSB's team. The collaboration with BlueSphere Bio is a significant strategic move that could enhance Celularity's revenue and market position in the cell therapy sector.

The MASS Coalition has welcomed a recent executive order from former President Trump that freezes the implementation of Local Coverage Determinations (LCDs) for skin substitutes. This order is seen as a significant step in supporting the use of skin substitutes, which could benefit companies like Celularity, Inc. that are involved in regenerative medicine and tissue engineering. The coalition advocates for policies that promote innovation and access to advanced therapies, and this order aligns with their goals. The executive order could significantly influence market dynamics and regulatory conditions for companies involved in skin substitutes and regenerative medicine.